<DOC>
	<DOCNO>NCT00362752</DOCNO>
	<brief_summary>The hepatopulmonary syndrome ( HPS ) pre-HPS disease see patient chronic liver disease , whereby patient develop dilation blood vessel lung , result low oxygen level shortness breath . In study , HPS pre-HPS subject treat commonly use antibiotic call `` norfloxacin '' ( approve use treatment gonorrhea , prostatitis urinary tract infection ) 4-week period . In order ensure observe improvement indeed due norfloxacin , subject also treat separate 4-week course identical placebo . There also 4 week wash-out period ( study medication/placebo ) 2 course treatment . The primary aim study measure improvement oxygen level norfloxacin , although number secondary parameter also follow .</brief_summary>
	<brief_title>A Pilot Study Norfloxacin Hepatopulmonary Syndrome</brief_title>
	<detailed_description>Research Question : This pilot study ; fundamental research question : Does norfloxacin administration reduce Alveolar-arterial oxygen gradient ( AaDO2 ) patient HPS pre-HPS ? However , particular pilot study , research question : What magnitude standard deviation change A-a gradient norfloxacin treatment subject HPS pre-HPS ? This order enable accurate sample size estimation future large randomized-controlled trial norfloxacin administration treatment HPS pre-HPS . Significance : HPS pre-HPS disease carry high morbidity alarmingly high mortality . Orthotopic liver transplantation ( OLT ) effective treatment , threaten significant operative mortality patient . A grow body literature build elegant compelling case role gut bacterial translocation secondary pulmonary nitric oxide ( NO ) overproduction pathophysiology HPS . A sophisticated rat model case report human subject support potential norfloxacin , widely available , cheap non-toxic antibiotic , mitigate effect improve oxygenation , important contributor morbidity mortality HPS . Given dismal prognosis disease , biological plausibility hypothesis , minimal foreseeable deleterious consequence intervention , behoove scientific community formally test theory . A . Objectives - evaluate magnitude standard deviation change AaDO2 norfloxacin treatment subject HPS pre-HPS , enable accurate sample size estimation future large randomized-controlled trial norfloxacin administration treatment HPS - evaluate subject recruitment retention , order determine feasibility future large randomized-controlled trial norfloxacin administration treatment HPS pre-HPS - qualitatively evaluate usefulness number new measure never utilize subject population ( baseline dyspnea index ( BDI ) , transitional dyspnea index ( TDI ) , Chronic Respiratory Disease Questionnaire ( CRQ ) - evaluate hypothesize role alveolar NO ( measure exhale NO ) intermediary relationship norfloxacin administration AaDO2 Methods i. Overview Study Design - intervention maneuver This single-university center ( University Toronto ) , randomize , control pilot study crossover design . The intervention exposure norfloxacin ( 400 mg po bid ) 4-week period , compare identical placebo treatment . In crossover design , subject receive norfloxacin placebo medication , order treatment randomize , detailed study maneuver , . Study maneuver : Eligible subject identify Drs . Faughnan Gupta . They subsequently recruit respirology research coordinator ( see detail ) . Next , hospital pharmacist provide subject 4-week supply either norfloxacin 400 mg po bid , identical placebo , accord pre-determined computerized randomization scheme . The pharmacist person aware treatment allocation throughout study ( subject , research coordinator , treat physician outcome assessor blind ) . After initial 4-week treatment , 4-week washout period , pharmacist provide subject 4-week supply alternative agent ( crossover ) ( see figure 2 ) . ii . Measurements - outcome Outcomes The primary endpoint study difference change AaDO2 treatment course , treatment placebo group . The secondary endpoint include partial pressure arterial oxygen ( paO2 ) , exhale NO , diffusion lung capacity carbon monoxide ( DLCO ) , cardiac output ( CO ) , total peripheral resistance ( TPR ) , pulmonary artery systolic pressure ( PAP ) ( echocardiogram ) , endotoxin level , endothelin-1 ( ET-1 ) level , MELD score ( model end-stage liver disease ) ( base creatinine , bilirubin INR ) , baseline dyspnea index ( BDI ) , transitional dyspnea index ( TDI ) , Chronic Respiratory Disease Questionnaire ( CRQ ) . Assessment Outcomes Please see attach `` procedure table , '' `` data collection sheet . '' Once randomize , subject undergo initial assessment time 0 ( week 0 ) , : 1 . ABG ( pO2 , AaDO2 ) 2. pulmonary function test : exhale NO , DLCO 3 . BP , echocardiogram : CO , TPR , PAP 4. blood test : INR , bilirubin , creatinine ( MELD score ) , liver enzymes ( ALT , AST , ALP , bilirubin ) , albumin , endotoxin level , ET-1 level 5. questionnaire : BDI/TDI , CRQ 6. history physical exam study physician All measure repeat 4 week ( end first treatment course ) , 8 week ( start next treatment course ) , 12 week ( end second treatment course ) . In addition , ABG exhale NO alone repeat 2 week 10 week ( midway treatment period ) . Finally , blood ( 40 ml ) drawn time 0 , 4 , 8 , 12 week store measurement future variable .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hepatopulmonary Syndrome</mesh_term>
	<mesh_term>Norfloxacin</mesh_term>
	<criteria>Diagnosis HPS , base following : evidence portal hypertension ( esophagogastric varix portal hypertensive gastropathy identify esophagogastroduodenoscopy , and/or varix see computerize tomography ( CT ) scan ultrasound , and/or splenomegaly explanation , and/or ascites explanation , and/or hepatic vein wedge pressure great 12 mm Hg ) Intrapulmonary shunt contrast echocardiography ( CE ) AaDO2 great 20 mm Hg standing , room air arterial blood gas ( ABG ) OR PreHPS elevate exhale Nitric Oxide : evidence portal hypertension ( esophagogastric varix portal hypertensive gastropathy identify esophagogastroduodenoscopy , and/or varix see computerize tomography ( CT ) scan ultrasound , splenomegaly explanation , and/or ascites explanation , and/or hepatic vein wedge pressure great 12 mm Hg ) IPVDs diagnose contrast echocardiography ( CE ) exhale nitric oxide level great 12.6 ppb Significant preexist respiratory disease ( case , diagnosis HPS preHPS uncertain , give observe elevation AaDO2 may underlie lung disease ) : force expiratory volume 1 second ( FEV1 ) less 70 percent predict forced vital capacity ( FVC ) less 70 percent predict FEV1/FVC le 0.7 inability perform pulmonary function test ( reason , important document normal underlying lung function ) echocardiographic estimate right ventricular systolic pressure 50 mm Hg right heart catheterization mean pulmonary artery pressure great 25 mm Hg ( pulmonary hypertension may result progressive hypoxemia due intracardiac shunt right ventricular failure ) inadequate echocardiographic window allow accurate transthoracic contrast ( bubble ) echocardiogram ( CE ) ( test use identify IPVDs ) antibiotic use within last 1 month ( intervention test ) ( note subject concurrent care gastroenterologist hepatologist , patient may accordingly prophylactic antibiotic therapy prior SBP variceal hemorrhage ; patient exclude ) ( 20 percent expect rate exclusion due criterion ) current use exogenous nitrate ( may increase exhale NO level ) norfloxacin intolerance ( norfloxacin administration study intervention ) : allergy intolerance norfloxacin fluoroquinolones history tendon rupture associate norfloxacin fluoroquinolones glucose 6phosphate dehydrogenase deficiency ( possibility hemolytic reaction norfloxacin ) know prolongation QTc interval duration &gt; 50 % RR interval , subject take QTcinterval prolong drug , subject uncorrected hypokalemia , clinically significant bradyarrhythmias acute myocardial ischemia ( norfloxacin may worsen ) pregnancy ( norfloxacin contraindicate ) age le 18 great 70 expect death/transplantation within 3 mo ( treat physician 's discretion ) lactose intolerance ( placebo contains lactose ) Smoking within last 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>norfloxacin</keyword>
	<keyword>hepatopulmonary syndrome</keyword>
</DOC>